{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dapagliflozin+%2B+Metformin&page=2",
    "query": {
      "intervention": "Dapagliflozin + Metformin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 38,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dapagliflozin+%2B+Metformin&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dapagliflozin+%2B+Metformin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T11:51:07.164Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01606007",
      "title": "Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching with Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching with Saxagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1282,
      "start_date": "2012-07",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-11-15T11:51:07.164Z",
      "location_count": 80,
      "location_summary": "Birmingham, Alabama • Homewood, Alabama • Muscle Shoals, Alabama + 73 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01606007"
    },
    {
      "nct_id": "NCT02419612",
      "title": "A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Glimepiride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 444,
      "start_date": "2015-08-14",
      "completion_date": "2019-09-18",
      "has_results": true,
      "last_update_posted_date": "2020-06-23",
      "last_synced_at": "2026-11-15T11:51:07.164Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Tempe, Arizona + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02419612"
    },
    {
      "nct_id": "NCT02229396",
      "title": "Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Exantide with Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Exentide",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 695,
      "start_date": "2014-09-04",
      "completion_date": "2017-12-28",
      "has_results": true,
      "last_update_posted_date": "2018-12-31",
      "last_synced_at": "2026-11-15T11:51:07.164Z",
      "location_count": 76,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 61 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tuscumbia",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02229396"
    },
    {
      "nct_id": "NCT02551874",
      "title": "A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Saxagliptin, Onglyza",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin, Farxiga",
          "type": "DRUG"
        },
        {
          "name": "Glargine insulin",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 650,
      "start_date": "2015-10-20",
      "completion_date": "2017-11-10",
      "has_results": true,
      "last_update_posted_date": "2018-12-11",
      "last_synced_at": "2026-11-15T11:51:07.164Z",
      "location_count": 20,
      "location_summary": "Anaheim, California • Los Angeles, California • Miami, Florida + 15 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02551874"
    },
    {
      "nct_id": "NCT02338193",
      "title": "Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Prevention in Women After GDM Who Are at High-risk"
      ],
      "interventions": [
        {
          "name": "DAPA/MET XR",
          "type": "DRUG"
        },
        {
          "name": "DAPA",
          "type": "DRUG"
        },
        {
          "name": "MET XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Woman's",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 69,
      "start_date": "2015-09-22",
      "completion_date": "2019-03-13",
      "has_results": true,
      "last_update_posted_date": "2019-06-11",
      "last_synced_at": "2026-11-15T11:51:07.164Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02338193"
    },
    {
      "nct_id": "NCT05161429",
      "title": "BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "DPP4",
          "type": "DRUG"
        },
        {
          "name": "GLP-1 receptor agonist",
          "type": "DRUG"
        },
        {
          "name": "Basal Insulin",
          "type": "DRUG"
        },
        {
          "name": "SLGT2",
          "type": "DRUG"
        },
        {
          "name": "SU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 550000,
      "start_date": "2021-07-01",
      "completion_date": "2024-06-30",
      "has_results": false,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-11-15T11:51:07.164Z",
      "location_count": 5,
      "location_summary": "Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Beachwood",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05161429"
    },
    {
      "nct_id": "NCT00528372",
      "title": "A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin placebo",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "77 Years",
        "sex": "ALL",
        "summary": "18 Years to 77 Years"
      },
      "enrollment_count": 1067,
      "start_date": "2007-09",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2015-10-20",
      "last_synced_at": "2026-11-15T11:51:07.164Z",
      "location_count": 38,
      "location_summary": "Phoenix, Arizona • Tempe, Arizona • Fresno, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Gatos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00528372"
    },
    {
      "nct_id": "NCT02637037",
      "title": "A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bioequivalence",
        "Fixed Dose Combination Tablets",
        "Healthy Male and Female Subjects"
      ],
      "interventions": [
        {
          "name": "dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)",
          "type": "DRUG"
        },
        {
          "name": "dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)",
          "type": "DRUG"
        },
        {
          "name": "dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)",
          "type": "DRUG"
        },
        {
          "name": "dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 80,
      "start_date": "2015-12-21",
      "completion_date": "2016-04-07",
      "has_results": true,
      "last_update_posted_date": "2018-03-13",
      "last_synced_at": "2026-11-15T11:51:07.164Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02637037"
    },
    {
      "nct_id": "NCT00859898",
      "title": "Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR",
          "type": "DRUG"
        },
        {
          "name": "dapagliflozin matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "metformin HCl Modified Release matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "77 Years",
        "sex": "ALL",
        "summary": "18 Years to 77 Years"
      },
      "enrollment_count": 1093,
      "start_date": "2009-04",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2016-07-07",
      "last_synced_at": "2026-11-15T11:51:07.164Z",
      "location_count": 64,
      "location_summary": "Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more",
      "locations": [
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00859898"
    },
    {
      "nct_id": "NCT03249506",
      "title": "Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dipeptidyl Peptidase-4 Inhibitor (DPP-4)",
          "type": "DRUG"
        },
        {
          "name": "Glucagon-Like Peptide-1 Agonist (GLP-1)",
          "type": "DRUG"
        },
        {
          "name": "Thiazolidinedione (TZD)",
          "type": "DRUG"
        },
        {
          "name": "Sulfonylureas",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25358,
      "start_date": "2016-05-12",
      "completion_date": "2017-11-01",
      "has_results": false,
      "last_update_posted_date": "2017-11-21",
      "last_synced_at": "2026-11-15T11:51:07.164Z",
      "location_count": 1,
      "location_summary": "Trevose, Pennsylvania",
      "locations": [
        {
          "city": "Trevose",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03249506"
    }
  ]
}